IBDEI1XT ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30941,1,3,0)
;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30941,1,4,0)
;;=4^N07.6
;;^UTILITY(U,$J,358.3,30941,2)
;;=^5015565
;;^UTILITY(U,$J,358.3,30942,0)
;;=N07.7^^123^1597^27
;;^UTILITY(U,$J,358.3,30942,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30942,1,3,0)
;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30942,1,4,0)
;;=4^N07.7
;;^UTILITY(U,$J,358.3,30942,2)
;;=^5015566
;;^UTILITY(U,$J,358.3,30943,0)
;;=N07.8^^123^1597^30
;;^UTILITY(U,$J,358.3,30943,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30943,1,3,0)
;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
;;^UTILITY(U,$J,358.3,30943,1,4,0)
;;=4^N07.8
;;^UTILITY(U,$J,358.3,30943,2)
;;=^5015567
;;^UTILITY(U,$J,358.3,30944,0)
;;=N07.9^^123^1597^31
;;^UTILITY(U,$J,358.3,30944,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30944,1,3,0)
;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
;;^UTILITY(U,$J,358.3,30944,1,4,0)
;;=4^N07.9
;;^UTILITY(U,$J,358.3,30944,2)
;;=^5015568
;;^UTILITY(U,$J,358.3,30945,0)
;;=N08.^^123^1597^21
;;^UTILITY(U,$J,358.3,30945,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30945,1,3,0)
;;=3^Glomerular disorders in diseases classified elsewhere
;;^UTILITY(U,$J,358.3,30945,1,4,0)
;;=4^N08.
;;^UTILITY(U,$J,358.3,30945,2)
;;=^5015569
;;^UTILITY(U,$J,358.3,30946,0)
;;=C90.00^^123^1598^10
;;^UTILITY(U,$J,358.3,30946,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30946,1,3,0)
;;=3^Multiple myeloma not having achieved remission
;;^UTILITY(U,$J,358.3,30946,1,4,0)
;;=4^C90.00
;;^UTILITY(U,$J,358.3,30946,2)
;;=^5001752
;;^UTILITY(U,$J,358.3,30947,0)
;;=C90.01^^123^1598^9
;;^UTILITY(U,$J,358.3,30947,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30947,1,3,0)
;;=3^Multiple myeloma in remission
;;^UTILITY(U,$J,358.3,30947,1,4,0)
;;=4^C90.01
;;^UTILITY(U,$J,358.3,30947,2)
;;=^267515
;;^UTILITY(U,$J,358.3,30948,0)
;;=C90.02^^123^1598^8
;;^UTILITY(U,$J,358.3,30948,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30948,1,3,0)
;;=3^Multiple myeloma in relapse
;;^UTILITY(U,$J,358.3,30948,1,4,0)
;;=4^C90.02
;;^UTILITY(U,$J,358.3,30948,2)
;;=^5001753
;;^UTILITY(U,$J,358.3,30949,0)
;;=E11.29^^123^1598^21
;;^UTILITY(U,$J,358.3,30949,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30949,1,3,0)
;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
;;^UTILITY(U,$J,358.3,30949,1,4,0)
;;=4^E11.29
;;^UTILITY(U,$J,358.3,30949,2)
;;=^5002631
;;^UTILITY(U,$J,358.3,30950,0)
;;=E11.21^^123^1598^20
;;^UTILITY(U,$J,358.3,30950,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30950,1,3,0)
;;=3^Type 2 DM w/ Diabetic nephropathy
;;^UTILITY(U,$J,358.3,30950,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,30950,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,30951,0)
;;=E11.22^^123^1598^19
;;^UTILITY(U,$J,358.3,30951,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30951,1,3,0)
;;=3^Type 2 DM w/ Diabetic CKD
;;^UTILITY(U,$J,358.3,30951,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,30951,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,30952,0)
;;=E10.29^^123^1598^18
;;^UTILITY(U,$J,358.3,30952,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30952,1,3,0)
;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
;;^UTILITY(U,$J,358.3,30952,1,4,0)
;;=4^E10.29
;;^UTILITY(U,$J,358.3,30952,2)
;;=^5002591
;;^UTILITY(U,$J,358.3,30953,0)
;;=E10.21^^123^1598^17
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XT 3774 printed Dec 13, 2024@02:17:53 Page 2
IBDEI1XT ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30941,1,3,0)
+2 ;;=3^Hereditary nephropathy, NEC w/ dense deposit disease
+3 ;;^UTILITY(U,$J,358.3,30941,1,4,0)
+4 ;;=4^N07.6
+5 ;;^UTILITY(U,$J,358.3,30941,2)
+6 ;;=^5015565
+7 ;;^UTILITY(U,$J,358.3,30942,0)
+8 ;;=N07.7^^123^1597^27
+9 ;;^UTILITY(U,$J,358.3,30942,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,30942,1,3,0)
+12 ;;=3^Hereditary nephropathy, NEC w/ diffuse crescentic glomrlneph
+13 ;;^UTILITY(U,$J,358.3,30942,1,4,0)
+14 ;;=4^N07.7
+15 ;;^UTILITY(U,$J,358.3,30942,2)
+16 ;;=^5015566
+17 ;;^UTILITY(U,$J,358.3,30943,0)
+18 ;;=N07.8^^123^1597^30
+19 ;;^UTILITY(U,$J,358.3,30943,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,30943,1,3,0)
+22 ;;=3^Hereditary nephropathy, NEC w/ oth morphologic lesions
+23 ;;^UTILITY(U,$J,358.3,30943,1,4,0)
+24 ;;=4^N07.8
+25 ;;^UTILITY(U,$J,358.3,30943,2)
+26 ;;=^5015567
+27 ;;^UTILITY(U,$J,358.3,30944,0)
+28 ;;=N07.9^^123^1597^31
+29 ;;^UTILITY(U,$J,358.3,30944,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,30944,1,3,0)
+32 ;;=3^Hereditary nephropathy, NEC w/ unsp morphologic lesions
+33 ;;^UTILITY(U,$J,358.3,30944,1,4,0)
+34 ;;=4^N07.9
+35 ;;^UTILITY(U,$J,358.3,30944,2)
+36 ;;=^5015568
+37 ;;^UTILITY(U,$J,358.3,30945,0)
+38 ;;=N08.^^123^1597^21
+39 ;;^UTILITY(U,$J,358.3,30945,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,30945,1,3,0)
+42 ;;=3^Glomerular disorders in diseases classified elsewhere
+43 ;;^UTILITY(U,$J,358.3,30945,1,4,0)
+44 ;;=4^N08.
+45 ;;^UTILITY(U,$J,358.3,30945,2)
+46 ;;=^5015569
+47 ;;^UTILITY(U,$J,358.3,30946,0)
+48 ;;=C90.00^^123^1598^10
+49 ;;^UTILITY(U,$J,358.3,30946,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,30946,1,3,0)
+52 ;;=3^Multiple myeloma not having achieved remission
+53 ;;^UTILITY(U,$J,358.3,30946,1,4,0)
+54 ;;=4^C90.00
+55 ;;^UTILITY(U,$J,358.3,30946,2)
+56 ;;=^5001752
+57 ;;^UTILITY(U,$J,358.3,30947,0)
+58 ;;=C90.01^^123^1598^9
+59 ;;^UTILITY(U,$J,358.3,30947,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,30947,1,3,0)
+62 ;;=3^Multiple myeloma in remission
+63 ;;^UTILITY(U,$J,358.3,30947,1,4,0)
+64 ;;=4^C90.01
+65 ;;^UTILITY(U,$J,358.3,30947,2)
+66 ;;=^267515
+67 ;;^UTILITY(U,$J,358.3,30948,0)
+68 ;;=C90.02^^123^1598^8
+69 ;;^UTILITY(U,$J,358.3,30948,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,30948,1,3,0)
+72 ;;=3^Multiple myeloma in relapse
+73 ;;^UTILITY(U,$J,358.3,30948,1,4,0)
+74 ;;=4^C90.02
+75 ;;^UTILITY(U,$J,358.3,30948,2)
+76 ;;=^5001753
+77 ;;^UTILITY(U,$J,358.3,30949,0)
+78 ;;=E11.29^^123^1598^21
+79 ;;^UTILITY(U,$J,358.3,30949,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,30949,1,3,0)
+82 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
+83 ;;^UTILITY(U,$J,358.3,30949,1,4,0)
+84 ;;=4^E11.29
+85 ;;^UTILITY(U,$J,358.3,30949,2)
+86 ;;=^5002631
+87 ;;^UTILITY(U,$J,358.3,30950,0)
+88 ;;=E11.21^^123^1598^20
+89 ;;^UTILITY(U,$J,358.3,30950,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,30950,1,3,0)
+92 ;;=3^Type 2 DM w/ Diabetic nephropathy
+93 ;;^UTILITY(U,$J,358.3,30950,1,4,0)
+94 ;;=4^E11.21
+95 ;;^UTILITY(U,$J,358.3,30950,2)
+96 ;;=^5002629
+97 ;;^UTILITY(U,$J,358.3,30951,0)
+98 ;;=E11.22^^123^1598^19
+99 ;;^UTILITY(U,$J,358.3,30951,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,30951,1,3,0)
+102 ;;=3^Type 2 DM w/ Diabetic CKD
+103 ;;^UTILITY(U,$J,358.3,30951,1,4,0)
+104 ;;=4^E11.22
+105 ;;^UTILITY(U,$J,358.3,30951,2)
+106 ;;=^5002630
+107 ;;^UTILITY(U,$J,358.3,30952,0)
+108 ;;=E10.29^^123^1598^18
+109 ;;^UTILITY(U,$J,358.3,30952,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,30952,1,3,0)
+112 ;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
+113 ;;^UTILITY(U,$J,358.3,30952,1,4,0)
+114 ;;=4^E10.29
+115 ;;^UTILITY(U,$J,358.3,30952,2)
+116 ;;=^5002591
+117 ;;^UTILITY(U,$J,358.3,30953,0)
+118 ;;=E10.21^^123^1598^17
